A. G. Onishchenko
A. G. Onishchenko has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- A. S. Melnikova
Clinical Oncology Dispensary No. 1
1 shared publication - A. V. Lapshin
Clinical Oncologic Dispensary No. 1
1 shared publication - Anastasiya I. Stukan
Kuban State Medical University, Ministry of Health of Russia
1 shared publication - Anna Genrikhovna Kedrova
Federal Research and Clinical Center for Specialized Medical Care and Medical Technologies, Federal Biomedical Agency of the Russian Federation
1 shared publication - E. A. Nefyodova
Clinical Oncologic Dispensary No. 1
1 shared publication - E. V. Lymar
Clinical Oncologic Dispensary No. 1
1 shared publication
Latest Publications
- Open Access
- 2 September 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (2) , 49-61
Experience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia
This article presents a systematic review of international and domestic experience with the use of trastuzumab deruxtecan in patients with HER2-positive and HER2-low metastatic breast cancer. Based on an analysis of key registration studies (DESTINY-Breast01, -03, -04), and confirmatory clinical trials (DESTINY-Breast02, -12) and real-world clinical practice data from the Clinical Oncology Dispensary No. 1 (Krasnodar) (n = 22) and Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia (n = 6), the article summarizes the specifics of drug administration in the Russian healthcare setting, its efficacy profile, and manageable toxicity. A clinical case of a patient with HER2-positive mBC and brain metastases is described in detail, demonstrating long-term disease control (more than 15 months) with trastuzumab deruxtecan therapy in the second line after progression during treatment with a combination of trastuzumab, pertuzumab, and docetaxel. Practical recommendations for clinicians on monitoring the key adverse event – interstitial lung disease and pneumonitis – have been formulated.
- 2 September 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (2) , 49-61
Open AccessExperience with the use of trastuzumab deruxtecan in real-world clinical practice: data from Clinical Oncology Dispensary no. 1 (Krasnodar) and Federal Scientific Clinical Center of the fMBA of Russia
This article presents a systematic review of international and domestic experience with the use of trastuzumab deruxtecan in patients with HER2-positive and HER2-low metastatic breast cancer. Based on an analysis of key registration studies (DESTINY-Breast01, -03, -04), and confirmatory clinical trials (DESTINY-Breast02, -12) and real-world clinical practice data from the Clinical Oncology Dispensary No. 1 (Krasnodar) (n = 22) and Federal Scientific Clinical Center of the Federal Medical and Biological Agency of Russia (n = 6), the article summarizes the specifics of drug administration in the Russian healthcare setting, its efficacy profile, and manageable toxicity. A clinical case of a patient with HER2-positive mBC and brain metastases is described in detail, demonstrating long-term disease control (more than 15 months) with trastuzumab deruxtecan therapy in the second line after progression during treatment with a combination of trastuzumab, pertuzumab, and docetaxel. Practical recommendations for clinicians on monitoring the key adverse event – interstitial lung disease and pneumonitis – have been formulated.
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.
- 29 June 2026
- Published by "MedINK" Publishing House in Academy for Practical Oncology
- Vol. 1 (1)
Adenocystic cancer of minor salivary glands: peculiarities of clinical course
Adenoid cystic carcinoma of the minor salivary glands is a rare and aggressive form of malignant neoplasms characterized by hidden growth, rapid perineural advancement, tendency to develop local recurrences and distant metastases. This pathology is mostly seen in white women aged 50–60 years and is mostly localized in the sinonasal area and oral cavity. The article presents clinical cases of treatment of patients with adenoid cystic carcinoma of the sinonasal area and adenoid cystic carcinoma of the hard palate. Efficacy of off-label therapy as salvage therapy and an attempt to prolong life in incurable patients is demonstrated. Etiopathogenesis of this tumor is being investigated, and new treatment strategies are being developed, including targeted therapies.